GWT-TUD GmbH   Report issue

For profit Phase 2 Phase 3 Phase 4
Founded: Dresden https://www.gwtonline.de/assets/images/gfx/logo.png Germany (1996)

Organization Overview

First Clinical Trial
2005
NCT00558883
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

GWT-TUD GmbH

Active Ingredients

Drugs in Phase 4 Trials (12)

adapalene (differin) (1 trial)

benzoyl peroxide (clearasil) (1 trial)

clindamycin (cleocin) (1 trial)

dapagliflozin (farxiga) (1 trial)

empagliflozin (jardiance) (1 trial)

glimepiride (amaryl) (1 trial)

hydrochlorothiazide (esidrix) (1 trial)

insulin glargine (toujeo) (1 trial)

pazopanib (votrient) (1 trial)

ranibizumab (lucentis) (1 trial)

sitagliptin (januvia) (2 trials)

tretinoin (Retin-A) (1 trial)

Drugs in Phase 3 Trials (15)

acarbose (precose) (2 trials)

acetylsalicylic acid (aspirin) (1 trial)

carboplatin (paraplatin) (1 trial)

escherichia coli nissle 1917 (1 trial)

etoposide (vepesid) (1 trial)

ferric carboxymaltose (Injectafer) (1 trial)

fondaparinux sodium (arixtra) (1 trial)

ifosfamide (ifex) (1 trial)

luspatercept (Reblozyl) (1 trial)

nicotine (nicorette) (1 trial)

polatuzumab vedotin (Polivy) (1 trial)

rituximab (rituxan) (1 trial)

rivaroxaban (xarelto) (2 trials)

sodium chloride (1 trial)

urokinase (kinlytic) (1 trial)

Drugs in Phase 2 Trials (26)

allogeneic bone marrow derived mesenchymal stem cell (1 trial)

azacitidine (vidaza) (2 trials)

bemcentinib (1 trial)

cyclophosphamide (cytoxan) (1 trial)

cytarabine (cytosar-u) (1 trial)

daunorubicin (cerubidine) (1 trial)

dexamethasone (1 trial)

docetaxel (taxotere) (1 trial)

durvalumab (imfinzi) (1 trial)

emicizumab (Hemlibra) (1 trial)

fish oil (Omegavan) (1 trial)

fluorouracil (efudex) (1 trial)

folic acid (1 trial)

gemcitabine (gemzar) (1 trial)

ipilimumab (yervoy) (1 trial)

ixazomib (ninlaro) (1 trial)

lenalidomide (revlimid) (1 trial)

nivolumab (opdivo) (1 trial)

oxaliplatin (eloxatin) (1 trial)

paclitaxel (taxol) (1 trial)

pomalidomide (pomalyst) (1 trial)

ponatinib (iclusig) (1 trial)

relatlimab (Opdualag) (1 trial)

romidepsin (istodax) (1 trial)

secukinumab (cosentyx) (1 trial)

talacotuzumab (1 trial)

Drugs in Other Trials (3)

alirocumab (praluent) (1 trial)

evolocumab (repatha) (1 trial)

immune globulin (human) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acne Vulgaris (Phase 4)

Adenocarcinoma (Phase 2)

Aggression (Phase 2)

Anemia, Iron-Deficiency (Phase 3)

Cardiovascular Diseases (Phase 3)

Dermatitis (Phase 2)

Dermatitis, Atopic (Phase 2)

Diabetes Mellitus (Phase 4)

Diabetes Mellitus, Type 2 (Phase 4)

Diabetic Foot (Phase 3)

Dyslipidemias (Phase 3)

Edema (Phase 4)

Hemophilia A (Phase 2)

Hypoglycemia (Phase 4)

Inflammation (Phase 3)

Ischemia (Phase 3)

Leukemia (Phase 2)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive (Phase 2)

Leukemia, Myeloid (Phase 2)

Leukemia, Myeloid, Acute (Phase 2)

Leukemia, Myeloid, Chronic-Phase (Phase 2)

Lymphoma (Phase 2)

Lymphoma, B-Cell (Phase 2)

Lymphoma, Non-Hodgkin (Phase 2)

Lymphoma, T-Cell (Phase 2)

Macular Edema (Phase 4)

Metabolic Syndrome (Phase 3)

Multiple Myeloma (Phase 2)

Myelodysplastic Syndromes (Phase 2)

Neoplasms, Plasma Cell (Phase 2)

Neurodermatitis (Phase 2)

Pancreatic Neoplasms (Phase 2)

Preleukemia (Phase 2)

Sarcoma (Phase 4)

Sepsis (Phase 2)

Stomach Neoplasms (Phase 2)

Syndrome (Phase 3)

Thrombosis (Phase 3)

Venous Thrombosis (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 30
  • # of Trial APIs: 56